TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00759122

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: venlafaxine (Effexor)
Description: Matching capsules containing venlafaxine 37.5 mg. WERE prepared by the UCLA Pharmacy for the initial phase of the study. After a one-week placebo lead-in, subjects WERE randomly assigned to receive one capsule of either venlafaxine or placebo, with the dosage increase every two days until subjects received four capsules daily (subjects achieved a dose of 150 mg. of venlafaxine after 10 days). The first dose was administered in the morning, with subsequent capsules added on a b.i.d. schedule.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Matching capsules containing placebo 37.5 mg. WERE prepared by the UCLA Pharmacy for the initial phase of the study. After a one-week placebo lead-in, subjects WERE randomly assigned to receive one capsule of either venlafaxine or placebo, with the dosage increase every two days until subjects received four capsules daily (subjects achieved a dose of 150 mg. of venlafaxine after 10 days). The first dose was administered in the morning, with subsequent capsules added on a b.i.d. schedule.
Study: NCT00746629

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: FOCUS
Description: Treatment will be delivered over a 20-week period. Participating children and at least one of their parents will attend weekly in-person clinic sessions. Treatment will consist of 20-25 minute meetings between the assigned interventionist and each child/parent pair to individualize treatment, with an emphasis on helping the family change eating and activity behaviors. Family meetings will be followed by separate child and parent group meetings lasting approximately 35-45 minutes. In both approaches, parents serve as primary implementers of the treatment for the child and, if overweight, for themselves. Group sessions provide education in diet and physical activity, parenting, and behavioral skills, although conditions differ in whether skills are prescribed or self-directed. Children and parents will be weighed at each clinic visit.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FOCUS
Description: Treatment will be delivered over a 20-week period. Participating children and at least one of their parents will attend weekly in-person clinic sessions. Treatment will consist of 20-25 minute meetings between the assigned interventionist and each child/parent pair to individualize treatment, with an emphasis on helping the family change eating and activity behaviors. Family meetings will be followed by separate child and parent group meetings lasting approximately 35-45 minutes. In both approaches, parents serve as primary implementers of the treatment for the child and, if overweight, for themselves. Group sessions provide education in diet and physical activity, parenting, and behavioral skills, although conditions differ in whether skills are prescribed or self-directed. Children and parents will be weighed at each clinic visit.
Study: NCT01593930

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lidocaine(IANB)
Description: Inferior alveolar nerve block using one 2% Lidocaine cartridge with 1/80000 epinephrine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 1 Articaine(Infiltration)
Description: Buccal infiltration of one 4% Articaine cartridge with 1/100000 epinephrine
Study: NCT01979601

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator
Study: NCT04160637

Intervention type: DIAGNOSTIC_TEST
Intervention: Immediate postoperative PTH serum sampling and cut-off value identification
Description: The patients will undergo immediate post-thyroidectomy PTH sampling in order to establish a cut-off value for identifying patients at risk for postoperative hypocalcemia within the first 5 postoperative days.

Intervention type: DIAGNOSTIC_TEST
Intervention: Immediate postoperative PTH serum sampling and cut-off value identification
Description: The patients will undergo immediate post-thyroidectomy PTH sampling in order to establish a cut-off value for identifying patients at risk for postoperative hypocalcemia within the first 5 postoperative days.
Study: NCT03700918

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DaVingiTR System
Description: DaVingiTR Tricuspid valve annuloplasty repair device
Study: NCT03332095

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doravirine (DOR)
Description: 100 mg of DOR administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF)
Description: DOR/3TC/TDF administered orally as a fixed-dose combination (as a tablet, 100 mg/300 mg/300 mg) once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antiretroviral (ARV) medications
Description: Participants in Cohort 1 received a combination of dolutegravir (DTG) or raltegravir (RAL) plus two nucleoside reverse transcriptase inhibitors (NRTIs). The ARV drugs were prescribed by participants' own health care providers and were not provided by the study.
Study: NCT01637883

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: benzydamine HCl
Description: 3 ml (4.5 mg) of benzydamine hydrochloride will be dripped on the cuff of the endotracheal tube 5 minutes prior to induction of general anesthesia
Study: NCT01179932

Intervention type: OTHER
Intervention: No Intervention Used
Description: Our study is observational; therefore, there is no type of intervention being used.
Study: NCT02431104

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 532-nm KTP/1064-nm Nd:YAG Dual-Pulse Duration Laser
Description: Cutera enlighten dual wavelength 532nm KTP/1064nm Nd:YAG laser
Study: NCT01593930

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 2 Articaine(Infiltration)
Description: Buccal infiltration of two 4% Articaine cartridges with 1/100000 epinephrine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lidocaine(IANB)+1Articaine(Infiltration)
Description: Inferior alveolar nerve block using one 2% Lidocaine cartridge with 1/80000 epinephrine + Buccal infiltration of one 4% Articaine cartridge with 1/100000 epinephrine
Study: NCT01181245

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FG-3019
Description: 3mg/kg IV, 10mg/kg IV, 15mg/kg IV, 25mg/kg, 35mg/kg IV, 45mg/kg IV - Biweekly, 35/17.5mg/kg, 45/22.5 mg/kg - Weekly
Study: NCT02069197

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ketogenic diet
Description: ketogenic diet will consist of 3:1\[fat\]:\[protein+carbohydrate\]weight ratio with 1600 kcal restriction. Diet will last 9 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Orlistat
Description: Orlistat 120 mg TID for 9 months; life style intervention with recommended caloric goal of 1600 kcal/day.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standardized diet
Description: Standardized diet treatment for 9 months with recommended caloric goal of 1600kcal/day.
Study: NCT04330690

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artesunate
Description: 2.4 mg/kg at 0 hours, 12 hours, 24 hours, and then daily for a total of 7 days plus standard of care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib
Description: 400 mg enterally daily for 14 days plus standard of care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: 5 mg/kg IV given one time, over 2 hours plus standard of care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 6 mg IV/oral for a further five days, followed by a five day taper of 4 mg x 2 days and 2 mg x 3 days, for a total 20 day steroid course. If randomized to standard of care, discontinue the corticosteroid on day 10

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LSALT Peptide
Description: 5 mg , 2 hour IV infusion once daily for up to 14 consecutive days
Study: NCT00307047

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: XIENCE V® Everolimus Eluting Coronary Stent
Description: Drug eluting stent implantation stent in the treatment of coronary artery disease.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TAXUS™ EXPRESS2™ Paclitaxel Eluting Coronary Stent
Description: Drug eluting stent implantation stent in the treatment of coronary artery disease.
Study: NCT00379769

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Description: Rosiglitazone maximum 8 mg per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Description: Rosiglitazone maximum 8 mg per day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulfonylurea
Description: Sulfonylurea (SU) maximum permitted daily dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulfonylurea
Description: Sulfonylurea (SU) maximum permitted daily dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfonylurea
Description: Sulfonylurea (SU) maximum permitted daily dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin maximum permitted daily dose .

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin maximum permitted daily dose .

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin maximum permitted daily dose .
Study: NCT02711319

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rTMS
Description: For real (active) rTMS, we applied 2 seconds duration bursts of 20 Hz (40 pulses/burst) with intertrain intervals of 28 seconds, for a total of 1800 pulses over 20 minutes

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham rTMS
Description: Sham Comparator: sham rTMS (SHAM GROUP)~For sham rTMS, the double cone coil was again held over the vertex, but it was disconnected from the main stimulator unit. Instead, a second coil (8-shaped) was connected to the MagStim stimulator, and discharged under the patient's pillow (2).
Study: NCT01115686

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Branched-chain aminoacids
Description: Branched-chain aminoacids will be orally administered in the form of capsules, at the rate of a capsule for physical 7 Kilograms weighty and a day. Every capsule containing 375 milligrams of branched-chain aminoacids.~The treatment will last 3 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be orally administered in the form of capsules, at the rate of a capsule for physical 7 Kilograms weighty and a day.~The treatment will last 3 weeks.
Study: NCT04775147

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensive BP lowering
Description: The aim is to achieve a systolic BP level of \<120mmHg within 1hour after successful recanalization and to maintain this BP level for the next 72 hours (or until hospital discharge or death of this should occur earlier)
Study: NCT03052348

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Polyethylene glycol hexadecyl ether & Betamethasone valerate cream 0.1%
Description: Polyethylene glycol hexadecyl ether -Moisturizer. Betamethasone valerate cream 0.1% -Topical steroid

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fusidic acid, polyethylene glycol hexadecyl ether & Betamethasone valerate cream 0.1%
Description: Polyethylene glycol hexadecyl ether -Moisturizer. Betamethasone valerate cream 0.1% -Topical steroid Fusidic Acid - Topical Antibiotic
Study: NCT02290925

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kothala Himbutu Biscuit
Description: Kothala Himbutu biscuit (containing Salacia reticulata extract) as a snack. This herb has been used by traditional physicians to control blood sugar.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Biscuit
Description: Placebo biscuit without the herbal extract of Kothala Himbutu (Salacia reticulate)
Study: NCT01614353

Intervention type: OTHER
Intervention: Electronic Diaries
Description: Participants (N=30) will maintain electronic diaries to record spontaneous thoughts and perceptions regarding the use of a newly prescribed drug over 30 days.

Intervention type: OTHER
Intervention: Hermeneutic Interviews
Description: Half of the enrolled participants (n=15) will participate in 2 hermeneutic interviews conducted in an interpretive phenomonological approach to generate an interpretation of the meaning of medication taking.
Study: NCT01107899

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clopidogrel
Description: taken orally, day one, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prasugrel
Description: taken orally, day one, single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prasugrel
Description: taken orally, day one, single dose
Study: NCT01726569

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: film and trained counseling
Description: Subjects will be asked to watch a 5-10 min film and participate in a 10-15 min pre-operative counseling session with a trained doctor/nurse. Subjects will also participate in a 5 min post-operative counseling session.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: traditional counseling
Description: Subjects will be not participate or participate in a pre-operative/post-operative counseling session with a rural hospital's doctor/nurse as usual traditional methods.

Intervention type: OTHER
Group type: OTHER
Intervention: traditional counseling
Description: Subjects will be not participate or participate in a pre-operative/post-operative counseling session with a rural hospital's doctor/nurse as usual traditional methods.
Study: NCT03020953

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise + Estrogen
Description: 12 weeks resistance training and estrogen patches

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise + Placebo
Description: 12 weeks resistance training and placebo patches
Study: NCT02531867

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Asfotase Alfa
Study: NCT04066517

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SBRT
Description: Multimodal-imaging guided SBRT for VT ablation.
Study: NCT00902798

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Enhancement Therapy
Description: An 18-month comprehensive, small group approach for the remediation of cognitive deficits in neurodevelopmental disorders consisting of individual sessions and 45 group training sessions in social cognition that are integrated with approximately 60 hours of computer assisted training in attention, memory, and problem solving skills.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enriched Supportive Therapy
Description: An 18-month intervention that uses individual supportive therapy to help adults learn about autism spectrum disorder, manage their emotions and stress, improve their social skills, and cope with everyday problems. Participants will learn about the impact of stress on their lives, and how to identify their own early cues of distress and apply effective coping strategies.
Study: NCT05747612

Intervention type: OTHER
Group type: OTHER
Intervention: Counseling and Coaching
Description: Counseling is the art of helping yourself, that is, a helping relationship based on a series of interventions and stimuli for creativity, aimed at pursuing and maintaining an ever better relational, social and existential quality of life. Coaching is a fundamentally action-oriented method, aimed at concrete changes, the improvement of performance and the achievement of objectives.
Study: NCT03985436

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trek for Surgical Success
Description: Cognitive behavioral therapy for pain
Study: NCT00273286

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: family diabetes management intervention
Description: a clinic-integrated, low intensity, multi-component behavioral intervention
Study: NCT04303507

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine or Hydroxychloroquine
Description: A loading dose of 10 mg base/ kg followed by 155 mg daily (250mg chloroquine phosphate salt or 200mg of or hydroxychloroquine sulphate) will be taken for 3 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02112890

Intervention type: OTHER
Intervention: Data collection
Description: Data of the selected subjects (through structured questionnaires and interviews) and stored serum samples obtained from the ENSANUT 2012. A subset database will be designed by the NIPH for the purpose of this study. Extracted data and laboratory results of the selected subjects will be captured in the study database.
Study: NCT00564148

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avastin
Description: 2,5 mg Avastin intravitreal injections every 4 weeks, 6 months consecutively
Study: NCT04259359

Intervention type: DRUG
Intervention: Insect Venom
Description: Patients will be treated with bee venom immunotherapy (protocol can be selected by patient). Blood samples are taken before starting VIT to determine specific immunoglobulin E (sIgE) Levels for bee venom components. Patients are sting challenged and the outcome will be recorded.
Study: NCT00701909

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine plus Ketamine
Description: Morphine 0.05 mg/kg (maximum dose of 4 mg) IV plus Ketamine 0.25 mg/kg IV. Then, Morphine 0.1 mg/kg (maximum dose of 8 mg) IV plus Saline IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Morphine plus Ketamine
Description: Morphine 0.05 mg/kg (maximum dose of 4 mg) IV plus Ketamine 0.25 mg/kg IV. Then, Morphine 0.1 mg/kg (maximum dose of 8 mg) IV plus Saline IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine plus Saline (placebo)
Description: Morphine 0.1 mg/kg (maximum dose of 8 mg) IV plus Saline IV. Then, Morphine 0.05 mg/kg (maximum dose of 4 mg) IV plus Ketamine 0.25 mg/kg IV.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Morphine plus Saline (placebo)
Description: Morphine 0.1 mg/kg (maximum dose of 8 mg) IV plus Saline IV. Then, Morphine 0.05 mg/kg (maximum dose of 4 mg) IV plus Ketamine 0.25 mg/kg IV.
Study: NCT02472002

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal cell therapy
Description: Name of the experimental cell preparation: Concentrated mesenchymal stem cells (MSCs) derived from autologous bone marrow~* Registry Type: autologous~* Qualitative and quantitative composition of the finished product: The product is a cell suspension consisting of mesenchymal stem cells (MSC) 40 x 106 MSC / ml suspended in human albumin (ALBUNORM ® 5% OCTAPHARMA France).~* Route of administration: endomyocardial injection~* Dose administered: 120-140 x106 MSC (mesenchymal stem cells)
Study: NCT02836288

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine 1.0 mg/kg mixed with syrup will be given by mouth once a day for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine 1.0 mg/kg mixed with syrup will be given by mouth once a day for 12 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo syrup will be given by mouth once a day for 12 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo syrup will be given by mouth once a day for 12 weeks.
Study: NCT02539849

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: FOS

Intervention type: DRUG
Group type: OTHER
Intervention: Adalimumab
Study: NCT02551211

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: blood drawn
Description: blood drawn

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgical resection of cancer
Study: NCT01118559

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM150
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM150
Description: oral
Study: NCT01142167

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Colonoscopy
Description: Standard colonoscopy will be used during colonoscopy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultra-thin colonoscopy
Description: Ultra-thin colonoscope will be used during colonoscopy
Study: NCT02147847

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video game based training 1
Description: 32 one-hour, home-based training sessions over 8 weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video game based training 2
Description: 32 one-hour, home-based training sessions over 8 weeks
Study: NCT01561482

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin treatment will be started at 500 mg twice daily (dose level -2), in order to minimize gastrointestinal discomfort and, if no gastrointestinal toxicity grade greater than 1, will be increased to 500 mg with breakfast/1000 mg at bedtime (dose level -1) 4 days later (+/- 1 day allowed). If no gastrointestinal toxicity grade greater than 1, it will be increased to 1000 mg twice daily (dose level 0) 10 days later (+/- 2 days allowed), which is the target dose for the remainder of the study. If gastrointestinal toxicity grade greater than 1 occurs during these first 4 weeks, the subject will be evaluated every 2 weeks until resolution of toxicity to grade less than or equal to 1 and, then, the metformin dose will be increased to the next dose level.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: The simvastatin dose at treatment initiation will be 20 mg once daily (dose level -1), taken at bedtime for 2 weeks. After these 2 weeks, the subject will have blood work and, if no AST/ALT/CPK elevation grade greater than 1, will be escalated to 40 mg once daily (dose level 0), taken at bedtime. If AST or ALT or CPK elevation grade greater than 1 during the first 2 weeks, the subject will be evaluated every 2 weeks until resolution of toxicity to grade less than or equal to 1, and then the simvastatin dose will be increased to dose level 0.
Study: NCT04183998

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trans-spinal Electrical Stimulation (tsES)
Description: Stimulation will be achieved with two self-adhesive stimulation electrodes attached to the dorsal aspect of the neck overlying the cervical vertebrae and two self-adhesive rectangular return electrodes placed over the shoulders. Spinal motor evoked potentials (sMEP) induced by trans-spinal electrical stimulation (parameters, 1 Hz with a 0.1-1 ms pulse width and monophasic waveform) to determine recruitment profiles of proximal and distal motor pools with increasing stimulation intensity ranging from 10 to 200 milliampere. Stimulation parameters for the therapeutic stimulation will be ranged from 5-40 Hz and 20-100 milliampere.
Study: NCT00910897

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Velcade-Dexamethasone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Velcade-Thalidomide-Dexamethasone